{"filing":{"accession_number":"0001839341-26-000013","cik":"0001839341","ticker":"CORZZ","company_name":"Core Scientific, Inc./tx","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"core-20260728.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839341/000183934126000013/core-20260728.htm"},"events":[{"id":20896,"run_id":18816,"accession_number":"0001839341-26-000013","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Core Scientific issued a press release on July 28, 2026 announcing Q2 2026 financial results for the quarter ended June 30, 2026, disclosing quarterly revenue of $164.2 million, gross profit of $70.0 million, net loss of $1,155.3 million (driven by warrant fair value changes), and adjusted EBITDA of $41.1 million, along with condensed consolidated financial statements and operating metrics.","company_name":"Core Scientific, Inc./tx","ticker":"CORZZ","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20399,"accession_number":"0001839341-26-000013","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Core Scientific issued a press release on July 28, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing quarterly revenue ($164.2M), gross profit ($70.0M), net loss ($1,155.3M), and adjusted EBITDA ($41.1M), along with condensed consolidated financial statements and operating metrics. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:07:43.004419+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20400,"accession_number":"0001839341-26-000013","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing Core Scientific's financial results, including revenue of $164.2 million, net loss of $1,155.3 million (driven by warrant fair value changes), and key operating metrics. The filing includes condensed consolidated financial statements (balance sheet, income statement, cash flows) and business developments. Item 7.01 incorporates Item 2.02 by reference, and Exhibit 99.1 contains the full earnings announcement with financial tables and conference call details.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:07:43.004419+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20399,"accession_number":"0001839341-26-000013","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Core Scientific issued a press release on July 28, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing quarterly revenue ($164.2M), gross profit ($70.0M), net loss ($1,155.3M), and adjusted EBITDA ($41.1M), along with condensed consolidated financial statements and operating metrics. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:07:43.004419+00:00","company_name":"Core Scientific, Inc./tx","ticker":"CORZZ","filing_date":"2026-07-28"},{"id":20400,"accession_number":"0001839341-26-000013","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing Core Scientific's financial results, including revenue of $164.2 million, net loss of $1,155.3 million (driven by warrant fair value changes), and key operating metrics. The filing includes condensed consolidated financial statements (balance sheet, income statement, cash flows) and business developments. Item 7.01 incorporates Item 2.02 by reference, and Exhibit 99.1 contains the full earnings announcement with financial tables and conference call details.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:07:43.004419+00:00","company_name":"Core Scientific, Inc./tx","ticker":"CORZZ","filing_date":"2026-07-28"}]}